Mentorship session with the Executive Vice President and Chief Medical Officer of Horizon Therapeutics




To Be Announced


Please join Jeff Sherman, Executive Vice President and Chief Medical Officer of Horizon Therepudics for an intimate roundtable discussion.

Our digital community will have the opportunity to partake in an intimate and candid discussion with a Q&A session.

For questions about the event: please email:

*YJP has a non-solicitation policy covering all of our conferences and events. In order to provide a distraction-free environment for our mentors, sponsors, attendees, and employees, we do not allow solicitation at our events by attendees or unauthorized parties without the express written permission or consent from YJP. The Corporation As A Citizen.” We will discuss the intersections of business, policy, public affairs and law that confront multinational public corporations and, in particular, focus on the obligations corporations owe to a broad array of stakeholders (e.g., investors, employees,, public and private sector creditors, communities, governments, activists and suppliers). 

E88603904c3dca49c0f821d87fc52559ccc2814c large
Dr. Jeffrey W. Sherman
executive vice president, development and regulatory affairs and chief medical officer at Horizon Therapeutics

Dr. Jeffrey W. Sherman joined Horizon in June 2009 as executive vice president, development and regulatory affairs and chief medical officer and throughout his time at Horizon has assumed various responsibilities in addition to chief medical officer.

Before joining Horizon, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. Before IDM Pharma, he served as vice president of clinical science at Takeda Global Research and Development and from September 2000 to June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm Inc. From October 1992 to August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle. Dr. Sherman started in industry at Squibb/Bristol-Myers Squibb from April 1988 to September 1992 in clinical pharmacology and clinical research.

Dr. Sherman currently serves as a Drug Information Association (DIA) liaison to the Clinical Trial Transformation Initiative (CTTI), a public-private partnership founded by the U.S. Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. From June 2009 to June 2010 he served as president and board member of the DIA. He also serves on the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process.

Register for this event